François Lokiec

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

Céline Berthon, Emmanuel Raffoux, Xavier Thomas et al. · The Lancet Haematology · 2016 · 431 citations

Medicine, Hematology, Pharmacology +7

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Sandy Amorim, Anastasios Stathis, Mary Gleeson et al. · The Lancet Haematology · 2016 · 428 citations

Medicine, Pharmacokinetics, Pharmacology +13

Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports

Ernesto Wasserman, Anne Myara, François Lokiec et al. · Annals of Oncology · 1997 · 213 citations

Pharmacy, Clinical Toxicology, Toxicologic Pathology +1

OTX015 (MK‐8628), a novel BET inhibitor, displays <i>in vitro</i> and <i>in vivo</i> antitumor effects alone and in combination with conventional therapies in glioblastoma models

Caroline Berenguer‐Daizé, Lucile Astorgues‐Xerri, Elodie Odore et al. · International Journal of Cancer · 2016 · 151 citations · Full text

Medicine, Oncology, Pharmacology +14

Population pharmacokinetics of total and unbound plasma cisplatin in adult patients

François Lokiec · British Journal of Clinical Pharmacology · 2004 · 150 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16